Earnings Call · Q4 FY2022·2023-03-28

Q4 22EPS -100.00%*·Rev n/aQ3 22EPS +7.14%·Rev n/aQ2 22EPS +28.57%·Rev n/aQ1 22EPS -45.45%·Rev n/a⚠ consensus missing

PDS Biotechnology Corp PDSB

Gabrielle DeGravina — Investor Relations / Conference Call Moderator

Frank Bedu-Addo — Chief Executive Officer

Lauren Wood — Chief Medical Officer

Matthew Hill — Chief Financial Officer

+3.0%1d on move date+3.2% vs SPY3d+3.2%5d+6.7%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more PDSB calls or request research access.

More PDSB calls Browse calls Request research access